U.S., April 5 -- ClinicalTrials.gov registry received information related to the study (NCT06911333) titled 'AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors' on March 17.
Brief Summary: The goal of this clinical trial is to evaluate the safety and tolerability of AD1208 to determine the maximum tolerated dose(MTD) or maximumly administered dose(MAD) in any progressive, locally advanced (unresectable) or metastatic solid tumors. The main questions it aims to answer are:
* Which dosage of AD1208 is safe and tolerable for participants?
* What medical problems do participants have when taking AD1208?
Participants will:
* Take drug AD1208 every day up to 1 cycle at the least.
* Visit the site once every...